Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study

Journal of Clinical Medicine 2026 Open access

Read full text
Authors: Antonello Veccia, Ettore D’Argento, Floriana Morgillo, Elio Gregory Pizzutilo, Fabiana Vitiello, Alberto Pavan, Fiorella Lombardo, M. Russano, Alessandro Morabito, Eleonora Gariazzo, C Genova, Rita Chiari
+21 more Antonella Cristofano, Alessandro Del Conte, Emanuela Vattemi, Alessandra Dessì, Daniele Galanti, Simona Busato, Giovanni Palazzolo, Clementina Savastano, Giuseppe Azzarello, Francesco Verderame, Cristina Mazzi, Daniela Bencardino, Mariachiara Dipasquale, Alessandro Scala, Carminia Maria Della Corte, Daniele Piscazzi, Marina Gilli, Emilio Bria, Orazio Caffo, Stefania Gori, Alessandro Inno
DOI: 10.3390/jcm15031165
Cited by: 1
References: 17

Abstract

Background: Chemoimmunotherapy combinations represent the standard first-line treatment for non-oncogene addicted metastatic NSCLC (mNSCLC). However, evidence in elderly patients remains limited and conflicting. We conducted an analysis of the efficacy and safety of chemoimmunotherapy in patients aged ≥75 years enrolled in the Real-Combo Lung study, an observational study including patients with non-oncogene-addicted mNSCLC and PD-L1 expression < 50%. Patients and Methods: The primary objective of the study was to compare progression-free survival (PFS) and overall survival (OS) between patients aged ≥75 (elderly cohort) and those aged

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Advanced Breast Cancer Therapies

Publication details

Journal / source
Journal of Clinical Medicine
Publisher
MDPI AG
Volume
15
Issue
3
Pages
1165–1165
Publication date
2 February 2026
Language
EN